Novel insights into the interaction between N6-methyladenosine modification and circular RNA

Wang, Shukui; He, Bangshun; Sun, Huiling; Xiong, Mengqiu; Nie, Junjie; Wang, Shukui; Pan, Yuqin

doi:10.1016/j.omtn.2022.01.007

Cited by 29 publications

(14 citation statements)

References 141 publications

(232 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bioinformatics analysis and experimental validation suggest that mmu_circRNA_004592 and mmu_circRNA_018351 are two functional important circRNAs [ 137 ]. N6-methyladenosine (m6A) modification of circRNAs participated in the pathogenesis of multiple diseases [ 138 ]. RNA-Seq of lung tissues in a hypoxia-induced rat PH model identified 166 upregulated m 6 A abundance circRNAs and 191 downregulated m6A abundance circRNAs.…”

Section: Circrnasmentioning

confidence: 99%

The Landscape of Noncoding RNA in Pulmonary Hypertension

et al. 2022

View full text Add to dashboard Cite

The transcriptome of pulmonary hypertension (PH) is complex and highly genetically heterogeneous, with noncoding RNA transcripts playing crucial roles. The majority of RNAs in the noncoding transcriptome are long noncoding RNAs (lncRNAs) with less circular RNAs (circRNAs), which are two characteristics gaining increasing attention in the forefront of RNA research field. These noncoding transcripts (especially lncRNAs and circRNAs) exert important regulatory functions in PH and emerge as potential disease biomarkers and therapeutic targets. Recent technological advancements have established great momentum for discovery and functional characterization of ncRNAs, which include broad transcriptome sequencing such as bulk RNA-sequence, single-cell and spatial transcriptomics, and RNA-protein/RNA interactions. In this review, we summarize the current research on the classification, biogenesis, and the biological functions and molecular mechanisms of these noncoding RNAs (ncRNAs) involved in the pulmonary vascular remodeling in PH. Furthermore, we highlight the utility and challenges of using these ncRNAs as biomarkers and therapeutics in PH.

show abstract

Section: Circrnasmentioning

confidence: 99%

The Landscape of Noncoding RNA in Pulmonary Hypertension

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A significant negative correlation between the TGF-β score and ICI-PFS was observed in OC, with an ICI-PFS of 16.6 months in the low TGF-β score group compared to 2.65 months in the high TGF-β score group (p = 0.0012). As the most common RNA modification, N6-methyladenosine (m6A) plays a key role in epigenetics ( 52 ). A risk model based on m6A-related targets has an excellent clinical prognostic stratification effect in advanced OC.…”

Section: Transcriptomic Signaturesmentioning

confidence: 99%

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer

Zuo

Wang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) therapy has evoked a prominent shift in anticancer therapy. Durable clinical antitumor activity to ICB has been observed in patients with ovarian cancer (OC). However, only a subset of patients derive clinical benefit, and immune-related adverse events (irAEs) caused by ICB therapy can lead to permanent tissue damage and even fatal consequences. It is thus urgent to develop predictive biomarkers to optimize patient outcomes and minimize toxicity risk. Herein, we review current predictive and prognostic biomarkers for checkpoint immunotherapy in OC and highlight emerging biomarkers to guide treatment with ICB. The prevalent biomarkers, such as PD-L1 expression status, tumor-infiltrating lymphocytes, mutational burden, and immune gene signatures, are further discussed. We provide a state-of-the-art survey on prognostic and predictive biomarkers for checkpoint immunotherapy and offer valuable information for guiding precision immunotherapy

show abstract

“…A lariat structure is produced by exon-skipping during pre-mRNA processing, which can then undergo internal splicing to form exon circRNAs or EIcircRNAs. In addition, increased N6-methyladenosine modification (m6A) levels are associated with the production of circRNAs [ 10 ]. Writers (methyltransferases), erasers (demethylases), or readers (RBPs) modulate the circularization of m6A exons [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

CircRNAs: versatile players and new targets in organ fibrosis

et al. 2023

View full text Add to dashboard Cite

Organ fibrosis can occur in virtually all major organs with relentlessly progressive and irreversible progress, ultimately resulting in organ dysfunction and potentially death. Unfortunately, current clinical treatments cannot halt or reverse the progression of fibrosis to end-stage organ failure, and thus, advanced antifibrotic therapeutics are urgently needed. In recent years, a growing body of research has revealed that circular RNAs (circRNAs) play pivotal roles in the development and progression of organ fibrosis through highly diverse mechanisms of action. Thus, manipulating circRNAs has emerged as a promising strategy to mitigate fibrosis across different organ types. In this review, we systemically summarize the current state of knowledge about circRNA biological properties and the regulatory mechanisms of circRNAs. A comprehensive overview of major fibrotic signaling pathways and representative circRNAs that are known to modulate fibrotic signals are outlined. Then, we focus on the research progress of the versatile functional roles and underlying molecular mechanisms of circRNAs in various fibrotic diseases in different organs, including the heart, liver, lung, kidney and skin. Finally, we offer a glimpse into the prospects of circRNA-based interference and therapy, as well as their utilization as biomarkers in the diagnosis and prognosis of fibrotic diseases.

show abstract

Novel insights into the interaction between N6-methyladenosine modification and circular RNA

Cited by 29 publications

References 141 publications

The Landscape of Noncoding RNA in Pulmonary Hypertension

The Landscape of Noncoding RNA in Pulmonary Hypertension

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer

CircRNAs: versatile players and new targets in organ fibrosis

Contact Info

Product

Resources

About